Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q2 2023 · 10-Q
Revenue$0.00$0.00no prior Q2 2022 on file Net Income-$144.14K-$144.14Kno prior Q2 2022 on file EPS Diluted$0.00$0.00no prior Q2 2022 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
Operating Cash Flowderived-$57,561— ended Jul 31, 2022 · filed Sep 15, 2022 · 46 d after period end